Impact of high-dose chemotherapy on peripheral T-cell lymphomas

Beyond maximum grade: key regulatory considerations in adverse event reporting.

The Lancet. Haematology·2026

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Large B-cell lymphoma: The LYSA pragmatic guidelines.

European journal of cancer (Oxford, England : 1990)·2025

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.

Blood advances·2025

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

The Patient Who Could Not Die.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Light Source-Dependent Photooxidation of Therapeutic Monoclonal Antibodies: A Comparative Study of Light-Emitting Diode (LED) and Fluorescent Exposure.

Pharmaceutical development and technology·2026

Single-cell immune profiling of blood and thrombus in cancer-associated thrombosis.

iScience·2026

BCR::ABL1 e1a2 (p190)-Positive Myeloid Blast Neoplasm: Diagnostic Challenges in Distinguishing De Novo Acute Myeloid Leukemia From Previously Unrecognized Chronic Myeloid Leukemia in the Blast Phase.

Cureus·2026

Myeloid sarcoma as EM blast crisis in BCR-ABL1 e6a2+ CML with myelofibrosis and TB: a case report.

Open life sciences·2026

Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.

EClinicalMedicine·2026

Related Experiment Videos

Impact of high-dose chemotherapy on peripheral T-cell lymphomas

Related Concept Videos

Beyond maximum grade: key regulatory considerations in adverse event reporting.

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Large B-cell lymphoma: The LYSA pragmatic guidelines.

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.

Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

The Patient Who Could Not Die.

Light Source-Dependent Photooxidation of Therapeutic Monoclonal Antibodies: A Comparative Study of Light-Emitting Diode (LED) and Fluorescent Exposure.

Single-cell immune profiling of blood and thrombus in cancer-associated thrombosis.

BCR::ABL1 e1a2 (p190)-Positive Myeloid Blast Neoplasm: Diagnostic Challenges in Distinguishing De Novo Acute Myeloid Leukemia From Previously Unrecognized Chronic Myeloid Leukemia in the Blast Phase.

Myeloid sarcoma as EM blast crisis in BCR-ABL1 e6a2+ CML with myelofibrosis and TB: a case report.

Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.

Related Experiment Videos

Impact of high-dose chemotherapy on peripheral T-cell lymphomas

Related Concept Videos

Related Articles